Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Autor:	Merita Rroji, Andreja Figurek, Goce Spasovski
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	chronic kidney disease uremic cardiopathy left ventricular hypertrophy phosphate pth fgf23 klotho sclerostin Medicine
Zdroj:	Toxins, Vol 12, Iss 3, p 140 (2020)
Druh dokumentu:	article
ISSN:	2072-6651
DOI:	10.3390/toxins12030140
Popis:	Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/9557c97cdfde4441ade726518eaedd5f Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.